These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33287744)

  • 1. TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.
    Naeser Y; Helgadottir H; Brandberg Y; Hansson J; Bagge RO; Elander NO; Ingvar C; Isaksson K; Flygare P; Nilsson C; Jakobsson F; Del Val Munoz O; Valachis A; Jansson M; Sparring C; Ohlsson L; Dyrke U; Papantoniou D; Sundin A; Ullenhag GJ
    BMC Cancer; 2020 Dec; 20(1):1197. PubMed ID: 33287744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma.
    Podlipnik S; Moreno-Ramírez D; Carrera C; Barreiro A; Manubens E; Ferrandiz-Pulido L; Sánchez M; Vidal-Sicart S; Malvehy J; Puig S
    Br J Dermatol; 2019 May; 180(5):1190-1197. PubMed ID: 29876940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
    Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.
    Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Wagenius G; Carstensen J; Hansson J
    Eur J Cancer; 2013 Aug; 49(12):2705-16. PubMed ID: 23583439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
    De Smedt J; Van Kelst S; Boecxstaens V; Stas M; Bogaerts K; Vanderschueren D; Aura C; Vandenberghe K; Lambrechts D; Wolter P; Bechter O; Nikkels A; Strobbe T; Emri G; Marasigan V; Garmyn M
    BMC Cancer; 2017 Aug; 17(1):562. PubMed ID: 28835228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial.
    Stoffels I; Herrmann K; Rekowski J; Jansen P; Schadendorf D; Stang A; Klode J
    Trials; 2019 Feb; 20(1):99. PubMed ID: 30717811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study).
    Naeser Y; Helgadottir H; Hansson J; Ingvar C; Elander NO; Flygare P; Nilsson C; Jakobsson F; Valachis A; Papantoniou D; Nordin Danfors A; Johansson H; Sundin A; Brandberg Y; Ullenhag GJ
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
    Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
    J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.
    Simberg-Danell C; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
    Int J Cancer; 2016 Aug; 139(3):543-53. PubMed ID: 27004457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.
    Macfarlane DJ; Sondak V; Johnson T; Wahl RL
    J Clin Oncol; 1998 May; 16(5):1770-6. PubMed ID: 9586890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
    Lyth J; Carstensen J; Synnerstad I; Lindholm C
    J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
    Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
    J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review.
    Krug B; Crott R; Lonneux M; Baurain JF; Pirson AS; Vander Borght T
    Radiology; 2008 Dec; 249(3):836-44. PubMed ID: 19011184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society.
    Garbe C; Orfanos CE
    Pigment Cell Res; 1992; Suppl 2():285-94. PubMed ID: 1409431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.
    Seegenschmiedt MH; Keilholz L; Altendorf-Hofmann A; Urban A; Schell H; Hohenberger W; Sauer R
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):607-18. PubMed ID: 10348291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.
    Sosman JA; Moon J; Tuthill RJ; Warneke JA; Vetto JT; Redman BG; Liu PY; Unger JM; Flaherty LE; Sondak VK
    Cancer; 2011 Oct; 117(20):4740-06. PubMed ID: 21455999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.